Study Details
Testing the Drug Nivolumab for Pediatric Patients with Recurrent or Progressive High-Grade Glioma
(IRB#: IRB_00142607)
Recurrent or progressive high-grade glioma (HGG) is a brain tumor that rapidly grows and spreads within the brain or spinal cord. This study will test a drug called nivolumab to treat pediatric patients with HGG. This study wants to see if the drug will help people with the disease and is safe. Participants will receive nivolumab for about 2 weeks before a scheduled surgery to remove the tumor and then again after the surgery. Study participation includes 2 years of treatment and about 5 years of follow-up. Medical tests and surveys will be done to track the health of participants.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Unpaid
Who can participate?
Gender: All genders
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 6 months to 25 years old
- Have recurrent or progressive high-grade glioma (HGG)
- History of previously treated HGG
- Able to have surgery to remove tumor
- Able to attend in-person visits at the study clinic
Exclusion Criteria
- Has a diagnosis of immunodeficiency
- Has tumor primarily localized to the brainstem or spinal cord
- Currently receiving another investigational drug
- Has a known history of active TB (Bacillus Tuberculosis)
- Prior allogenic hematopoietic stem cell transplant (HSCT)
Will I be paid for my time?
No
IRB#: IRB_00142607
PI: Nicholas Whipple
Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
Approval Date: 2021-11-18 07:00:00
Study Categories: Cancer Studies
Specialties: Pediatric Hematology & Oncology
I am Interested